Dublin medtech behind ReActiv8, an implantable device for chronic low back pain.
| Date | Round | Amount |
|---|---|---|
| Feb 2024 | Funding round Mainstay Medical raised $125m in equity financing led by Gilde Healthcare and Viking Global Investors to expand its ReActiv8 back-pain product across the US, Europe and Australia. | $125M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.